Literature DB >> 7437804

Debendox and congenital malformations in Northern Ireland.

D W Harron, K Griffiths, R G Shanks.   

Abstract

An investigation was carried out in Northern Ireland into the alleged association between fetal abnormalities and Debendox, an antiemetic drug used in pregnancy. During the period 1966-78 the total number of births each year and the overall incidence of congenital malformations per 10 000 births fell. The incidences of cleft lip, cleft palate, reduction deformities, and defects of the heart and great vessels fell from 1966 to 1976 but increased in 1977 and 1978. During the same period (1966-78) the number of prescriptions for Debendox issued by general practitioners increased more than fourfold. These observations suggest that there is no relation between congenital malformations and the use of Debendox. This conclusion, however, does not take into account other drug- or environmental-related factors that may have resulted in a reduction in the number of congenital malformations and would hence have masked an increase associated with greater usage of Debendox. In particular, the amount of Debendox sold direct to the public without a prescription and the use of the drug by patients who were not pregnant could not be established. The amount of drug used in these ways is probably small, and it is difficult to see how it might influence the conclusions reached.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7437804      PMCID: PMC1714994          DOI: 10.1136/bmj.281.6252.1379

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  5 in total

1.  Antenatal exposure to doxylamine succinate and dicyclomine hydrochloride (Benedectin) in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score.

Authors:  S Shapiro; O P Heinonen; V Siskind; D W Kaufman; R R Monson; D Slone
Journal:  Am J Obstet Gynecol       Date:  1977-07-01       Impact factor: 8.661

2.  Unusual fetal malformations after antiemetics in early pregnancy.

Authors:  R Harris
Journal:  Br Med J       Date:  1978-03-18

3.  CDC study: no evidence for teratogenicity of Bendectin.

Authors:  W A Check
Journal:  JAMA       Date:  1979-12-07       Impact factor: 56.272

4.  A comparison of neural tube defects identified by two independent routine recording systems for congenital malformations in Northern Ireland.

Authors:  N C Nevin; J R McDonald; A L Walby
Journal:  Int J Epidemiol       Date:  1978-12       Impact factor: 7.196

5.  Exogenous hormones and other drug exposures of children with congenital heart disease.

Authors:  K J Rothman; D C Fyler; A Goldblatt; M B Kreidberg
Journal:  Am J Epidemiol       Date:  1979-04       Impact factor: 4.897

  5 in total
  9 in total

1.  Antinauseants in pregnancy: teratogens or not?

Authors:  A Biringer
Journal:  Can Fam Physician       Date:  1984-10       Impact factor: 3.275

2.  The debendox saga.

Authors:  M L Orme
Journal:  Br Med J (Clin Res Ed)       Date:  1985-10-05

3.  Treatment of common minor ailments.

Authors:  C W Howden
Journal:  Br Med J (Clin Res Ed)       Date:  1986-12-13

4.  Bendectin: the wrong way to regulate drug availability.

Authors:  J S Leeder; S P Spielberg; S M MacLeod
Journal:  Can Med Assoc J       Date:  1983-11-15       Impact factor: 8.262

5.  Crying wolf on drug safety.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1982-01-23

6.  Clinical pharmacology. Drug monitoring.

Authors:  D C Moir
Journal:  Br Med J (Clin Res Ed)       Date:  1981-02-21

7.  Maternal drug histories and central nervous system anomalies.

Authors:  K A Winship; D A Cahal; J C Weber; J P Griffin
Journal:  Arch Dis Child       Date:  1984-11       Impact factor: 3.791

8.  Debendox in early pregnancy and fetal malformation.

Authors:  D M Fleming; J D Knox; D L Crombie
Journal:  Br Med J (Clin Res Ed)       Date:  1981-07-11

9.  Inter-Regional Epidemiological Study of Childhood Cancer (IRESCC): childhood cancer and the consumption of debendox and related drugs in pregnancy.

Authors:  P A McKinney; R A Cartwright; C A Stiller; P A Hopton; J R Mann; J M Birch; A L Hartley; J A Waterhouse; H E Johnston
Journal:  Br J Cancer       Date:  1985-12       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.